OmnySense
Digital health company with a proprietary personal health-assessment solution.
Company Overview
Snapshot
Founded in May 2019 by yossi aldar, Ian Solomon, and Amir Elhasid, OmnySense operates with 1–10 employees. The company has raised $1.5 million across two funding rounds. In November 2024, OmnySense was awarded a US patent for its smart thermometer integrated with 3/6-lead ECG technology.
Business overview
OmnySense is a digital health company focused on empowering individuals to make informed health decisions from home. The company develops a smart multi-sensor device paired with an AI-powered application that measures and interprets key clinical parameters, providing medical assessments. This technology helps users determine when to seek further medical attention. OmnySense serves individuals, healthcare systems, and the broader health industry, operating within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Medical Devices, with a focus on patient remote monitoring and medical monitors.
Strategic signal
In March 2025, OmnySense announced its strategic focus on oncology patients as an initial target for its personal health-assessment solution, alongside plans to disrupt respiratory health tracking with its patented technology. This indicates a clear strategic pivot towards specialized patient populations and highlights the company's intent to leverage its intellectual property for focused market penetration, signaling a move beyond general health assessment into more critical care areas for investors.
Log in to access full profile ›Company Intelligence Q&A
- What is OmnySense's core technology?
- OmnySense utilizes a smart multi-sensor device and an AI-powered application to measure and interpret key clinical parameters, providing immediate medical assessments at home. This technology is designed to help individuals make informed health decisions.
- When was OmnySense awarded a US patent for its smart thermometer?
- In November 2024, OmnySense was awarded a US patent for its smart thermometer, which features an integrated 3/6-lead ECG.
- What is OmnySense's strategic focus for its personal health-assessment solution?
- In March 2025, OmnySense announced its intention to target oncology patients as an initial focus for its transformative personal health-assessment solution.
- How is OmnySense impacting respiratory health tracking?
- In March 2025, OmnySense indicated it is poised to disrupt respiratory health tracking through its patented technology, building on a study from August 2024 that confirmed its innovative method for home-based respiratory assessment.